Keywords: Boehringer Ingelheim, Cancer drugs, Afatinib, NSCLC, Breast, Head and neck cancer, Nintedanib, Volasertib, GlboalData
Analysts view Boehringer Ingelheim's first move into cancer drug market
Article | 11 October 2012
German family-owned drug major Boehringer Ingelheim last month announced the submission of a Marketing Authorization Application (MAA) to the European ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
